2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2017
Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly
Campos A, Moura F, Santos S, Freitas W, Sposito A, Study O. Sarcopenia, but not excess weight or increased caloric intake, is associated with coronary subclinical atherosclerosis in the very elderly. Atherosclerosis 2017, 258: 138-144. PMID: 28129889, DOI: 10.1016/j.atherosclerosis.2017.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdiposityAge FactorsAged, 80 and overAsymptomatic DiseasesBody CompositionCoronary AngiographyCoronary Artery DiseaseCross-Sectional StudiesEndothelium, VascularEnergy IntakeExercise TestExercise ToleranceFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultidetector Computed TomographyMultivariate AnalysisMuscle StrengthMuscle, SkeletalNutrition AssessmentNutritional StatusOdds RatioOverweightProspective StudiesRisk FactorsSarcopeniaVasodilationWeight GainConceptsCoronary heart diseaseAssociated with subclinical atherosclerosisCoronary calcium scoreFlow-mediated dilationExcess weightSubclinical atherosclerosisOdds ratioFatty massMuscle massPhysical performance testsCoronary heart disease riskElderly individualsRisk of coronary heart diseaseAssociated with coronary heart diseaseCaloric intakeIncreased risk of coronary heart diseaseStudy of CohortsEndothelial dysfunctionCross-sectional studySkeletal muscle indexAssociated with flow-mediated dilationGait speedCardiac computed tomographyReduction of muscle massMultivariate regression model
2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryC-Reactive ProteinCoronary AngiographyDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2014
Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial
Figueiredo V, Vendrame F, Colontoni B, Quinaglia T, Matos-Souza J, Moura F, Coelho O, de Faria E, Sposito A. Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. Clinical Therapeutics 2014, 36: 961-966. PMID: 24768191, DOI: 10.1016/j.clinthera.2014.03.012.Peer-Reviewed Original ResearchConceptsEffects of extended-release niacinFlow-mediated dilationExtended-release niacinHDL-C levelsHDL-CEndothelial functionDay 7Reduced plasma concentrations of high-density lipoprotein cholesterolLow HDL-C levelsHDL-C levels <Plasma concentrations of high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolConcentrations of high-density lipoprotein cholesterolLow HDL-C.Low HDL-CHeme oxygenase-1 pathwayTreatment period 1C-reactive proteinPlasma HDL-CTreatment period 2Improving endothelial functionEffects of niacinTransfer protein activityShort-term effectsReduced plasma concentrations